Semax

Amino Acid Sequence:

Met-Glu-His-Phe-Pro-Gly-Pro

Chemical Formula:

C₃₇H₅₁N₉O₁₀S

CAS Registry Number:

80714-61-0

• Cognitive enhancement (memory, attention, learning)

• Neuroprotection in ischemia, hypoxia, and oxidative stress

• Stroke recovery & cerebrovascular support

• Anti‑inflammatory and antioxidant activity

• Stress‑response modulation

• Mood and motivation support

• Adjunctive potential in neurodegenerative disorders

Neurotrophic & Synaptic Effects

• Upregulates BDNF and related neurotrophic factors

• Enhances synaptic plasticity and learning pathways

• Supports long‑term potentiation (LTP)

Neurotransmitter Modulation

• Regulates dopaminergic and serotonergic systems

• Supports mood, motivation, and cognitive performance

• Helps stabilize monoamine balance under stress

Neuroprotection & Cellular Defense

• Exhibits antioxidant and anti‑inflammatory activity

• Provides anti‑hypoxic protection in ischemic conditions

• Supports neuronal survival during oxidative stress

Semax is not FDA‑approved and is considered an experimental neuropeptide in Western research. However, it has a long history of clinical use in Eastern Europe, where it is valued for its strong safety profile and broad neuroprotective potential. Its combination of promising early findings and substantial real‑world clinical experience continues to drive interest in nootropic and neuroprotective peptide research.

1. Ashmarin, I. P., Kamensky, A. A., & Yakhno, N. N. (1995). Peptide analogs of ACTH fragments and their neurotropic effects. Neuroscience and Behavioral Physiology, 25(4), 341–345.

2. Andreeva, L. A., et al. (2001). Semax increases expression of neurotrophins and supports neuronal survival under stress. Bulletin of Experimental Biology and Medicine, 131(6), 565–568.

3. Inozemtseva, L. S., et al. (2008). Effects of Semax on cognitive function and neurotransmitter regulation. Neuroscience and Behavioral Physiology, 38(3), 263–268.

4. Dolotov, O. V., et al. (2006). Mechanisms of Semax action: modulation of BDNF and neurotrophic pathways. Doklady Biological Sciences, 407, 56–58.

5. Neznamov, G. G., & Teleshova, E. S. (2009). Clinical evaluation of Semax in cognitive impairment and anxiety disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 109(3), 22–27.

6. Andreeva, L. A., et al. (2010). Semax as a neuroprotective agent in ischemic brain injury. Bulletin of Experimental Biology and Medicine, 149(5), 612–615.

7. Kamensky, A. A., et al. (2016). Semax and neuroplasticity: long‑term effects on learning and memory. Neuroscience and Behavioral Physiology, 46(8), 1001–1007.

CURRENT BATCH LOT NUMBER: XA112026-04-07

CERTIFICATE OF ANALYSIS – TGMPURE SEMAX 11 MG (XA112026-04-07)